The Value of King's Score as a Predictor of Risk of Hepatocellular Carcinoma among Egyptian Patients with Hepatitis C Virus-Related Cirrhosis

IF 0.4 Q4 ONCOLOGY
A. Metwally, Amal A Jouda
{"title":"The Value of King's Score as a Predictor of Risk of Hepatocellular Carcinoma among Egyptian Patients with Hepatitis C Virus-Related Cirrhosis","authors":"A. Metwally, Amal A Jouda","doi":"10.30476/MEJC.2021.85341.1275","DOIUrl":null,"url":null,"abstract":"Background: Hepatocellular carcinoma (HCC) is the fifth most prevalent cancer and the second leading cause of cancer-related deaths worldwide. Egypt is one of the African countries with a high incidence of HCC. The process of carcinogenesis in the liver, particularly in post-hepatitic necrosis, is related to the severity of liver damage and fibrosis. The present study aimed to investigate the utility of King’s score to identify patients at higher risk of developing HCC among patients with hepatitis C virus-related cirrhosis. \nMethod: 58 patients were included in this retrospective case-control study. They were divided into two groups; group I included 29 patients diagnosed with HCC and group II comprised 29 patients without HCC. King’s score was calculated for all the patients based on their pararmeters at the time of diagnosis and their records of one year prior to the diagnosis. \nResults: King’s score was significantly higher in group I, not only at the time of diagnosis (95.4±45.2 vs 24.23±7.4 P<0.001), but also when calculated from the patients’ records a year before the diagnosis (70.4±41.8 vs 17.46±8.2 P<0.001). \nConclusion: King’s score can diagnose higher risk of developing HCC up to one year before the appearance of focal lesion.","PeriodicalId":44005,"journal":{"name":"Middle East Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2021-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Middle East Journal of Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30476/MEJC.2021.85341.1275","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Hepatocellular carcinoma (HCC) is the fifth most prevalent cancer and the second leading cause of cancer-related deaths worldwide. Egypt is one of the African countries with a high incidence of HCC. The process of carcinogenesis in the liver, particularly in post-hepatitic necrosis, is related to the severity of liver damage and fibrosis. The present study aimed to investigate the utility of King’s score to identify patients at higher risk of developing HCC among patients with hepatitis C virus-related cirrhosis. Method: 58 patients were included in this retrospective case-control study. They were divided into two groups; group I included 29 patients diagnosed with HCC and group II comprised 29 patients without HCC. King’s score was calculated for all the patients based on their pararmeters at the time of diagnosis and their records of one year prior to the diagnosis. Results: King’s score was significantly higher in group I, not only at the time of diagnosis (95.4±45.2 vs 24.23±7.4 P<0.001), but also when calculated from the patients’ records a year before the diagnosis (70.4±41.8 vs 17.46±8.2 P<0.001). Conclusion: King’s score can diagnose higher risk of developing HCC up to one year before the appearance of focal lesion.
King评分对埃及丙型肝炎病毒相关肝硬化患者肝癌风险的预测价值
背景:肝细胞癌(Hepatocellular carcinoma,HCC)是全球第五大癌症,也是导致癌症相关死亡的第二大原因。埃及是HCC发病率较高的非洲国家之一。肝脏癌变过程,特别是肝后坏死过程,与肝损伤和纤维化的严重程度有关。本研究旨在探讨King评分在丙型肝炎病毒相关肝硬化患者中用于识别HCC风险较高的患者的效用。方法:对58例患者进行回顾性病例对照研究。他们被分成两组;第一组包括29名诊断为HCC的患者,第二组包括29例非HCC患者。King评分是根据所有患者在诊断时的助手和诊断前一年的记录计算得出的。结果:I组King’s评分显著高于对照组(95.4±45.2 vs 24.23±7.4 P<0.001),而且根据诊断前一年的患者记录计算(70.4±41.8 vs 17.46±8.2 P<0.001。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.80
自引率
0.00%
发文量
0
审稿时长
12 weeks
期刊介绍: Middle East Journal of Cancer (MEJC) is an international peer-reviewed journal which aims to publish high-quality basic science and clinical research in the field of cancer. This journal will also reflect the current status of research as well as diagnostic and treatment practices in the field of cancer in the Middle East, where cancer is becoming a growing health problem. Lastly, MEJC would like to become a model for regional journals with an international outlook. Accordingly, manuscripts from authors anywhere in the world will be considered for publication. MEJC will be published on a quarterly basis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信